A Double-blind, Placebo-controlled Pilot Study To Evaluate The Effect Of Calcium Fructoborate On Systemic Inflammation And Dyslipidemia Markers For Middle-aged People With Primary Osteoarthritis
Notes for this study:
||Mean and SD. Placebo: before 365 (20), after 380 (19). Lowest: before 364 (10), after 314 (14). Middle: before 340 (29), after 333 (16). Highest dose: before 358 (15), after 343 (15).
|Number of Subjects
In a randomized, double-blind, placebo-controlled trial, 72 participants with osteoarthritis were allocated to take 1.5, 3, or 6 mg of boron from calcium fructoborate, or placebo for 2 weeks.
Erythrocyte sedimentation rate was somewhat reduced in all boron groups, and increased considerably in the placebo group, and the same was the case for fibrinogen, though for the latter two, the greatest reduction was in the lowest dose group, and there was barely a reduction in the highest dose group. Triglycerides were most notably reduced in the 3 mg group, total cholesterol, and LDL in the 1.5 mg group, HDL was largely unaffected.